|本期目录/Table of Contents|

[1]宋小刚,汤吉超,陈永清.新型冠状病毒肺炎与心肌损伤研究进展[J].医学研究与战创伤救治(原医学研究生学报),2022,24(1):59-63.[doi:10.3969/j.issn.1672-271X.2022.01.013]
　SONG Xiao-gang,TANG Ji-chao,CHEN Yong-qing.Research advance in COVID-19 and myocardial injury[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(1):59-63.[doi:10.3969/j.issn.1672-271X.2022.01.013]
点击复制

新型冠状病毒肺炎与心肌损伤研究进展()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第24卷
期数:
2022年1期
页码:
59-63
栏目:
综述
出版日期:
2022-02-20

文章信息/Info

Title:
Research advance in COVID-19 and myocardial injury
作者:
宋小刚; 汤吉超; 陈永清
作者单位：730000兰州, 兰州大学第二临床医学院(宋小刚);730000兰州, 甘肃中医药大学研究生院(汤吉超);730000 兰州, 中国人民解放军联勤保障部队第九四○医院心内科(陈永清)
Author(s):
SONG Xiao-gang;  TANG Ji-chao ;  CHEN Yong-qing
(1.The Second Clinical Medical Collage of Lanzhou University，Lanzhou 730000，Gansu，China；2.The Graduate School of Gansu University of Chinese Medicine, Lanzhou 730000，Gansu，China；3.Department of Cardiology，the 940th Hospital of Joint Logistics Support Force of Chinese People’s Liberation Army，Lanzhou 730000，Gansu，China)
关键词:
新型冠状病毒肺炎; 心肌损伤; 危险因素; 临床表现; 可能机制
Keywords:
COVID-19;  myocardial injury;  risk factors;  clinical manifestations;  possible mechanisms
分类号:
R542.2
DOI:
10.3969/j.issn.1672-271X.2022.01.013
文献标志码:
A
摘要:
新型冠状病毒肺炎（COVID-19）不仅损伤呼吸系统，也可以导致心肌损伤。在合并心血管疾病的COVID-19患者中心肌损伤发生率更高。并发心肌损伤的COVID-19患者危重率和死亡率明显增加。文章就新型冠状病毒肺炎引起心肌损伤的危险因素、临床表现以及可能机制进行综述。
Abstract:
The COVID-19 not only damages the respiratory system, butcan also cause damage to the myocardial tissue. The incidence of myocardial damage is higher in COVID-19 patients with cardiovascular disease. The critical rate and mortality rate in COVID-19 patients complicated with myocardial injury have significantly increased. This paper reviews the risk factors, clinical manifestations and possible mechanisms of myocardial injury induced by COVID-19.

参考文献/References:

[1]Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J]. Cell, 2020, 181(2):271-280.
[2]Oudit GY, Pfeffer, MA. Plasma angiotensin-converting enzyme 2: novel biomarker in heart failure with implications for COVID-19[J]. Eur Heart J, 2020, 41(19):1818-1820.
[3]Kreutz R, Algharably E, Azizi M, et al. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19[J]. Cardiovasc Res, 2020, 116(10):1688-1699.
[4]Huang CL, Wang YM, Li XW, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223):497-506.
[5]Li NZ, Zhang SD, He B, et al. Retrospective Study of Risk Factors for Myocardial Damage in Patients with Critical Coronavirus Disease 2019, in Wuhan[J]. J Am Heart Assoc, 2020, 9(15):e016706.
[6]Zhou F, Yu T, Du RH, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohortstudy[J]. Lancet, 2020, 395(10229):1054-1062.
[7]Wu CM, Chen XY, Cai YP, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China[J]. JAMA Intern Med, 2020, 180(7):934-943.
[8]Ruan QR, Yang K, Wang WX, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China[J]. Intensive Care Med, 2020, 46(5):846-848.
[9]Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohortstudy[J]. Lancet, 2020, 395(10239):1763-1770.
[10]Guan W, Ni Z, Hu Y，et al. Clinical characteristics of coronavirus disease 2019 in China[J]. N Engl J Med, 2020, 382(18):1708-1720.
[11]Guo T，Fan YZ，Chen M，et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) [J]. JAMA Cardiol, 2020, 5(7):811-818.
[12]Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics，comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area[J]. JAMA, 2020, 323(20):2052-2059.
[13]Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy[J]. JAMA, 2020, 323(16):1574-1581.
[14]Wang DW, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China[J]. JAMA, 2020, 323(11):1061-1069.
[15]Li B, Yang J, Zhao FM, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China[J]. Clin Res Cardiol, 2020, 109(5):531-538.
[16]Xiong TY, Redwood S, Prendergast B, et al. Coronaviruses and the cardiovascular system: acute and long-term implications[J]. Eur Heart J, 2020, 41(19):1798-1800.
[17]Shi SB, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China[J]. JAMA Cardiol, 2020, 5(7):802-810.
[18]Vaduganathan M, Vardeny O, Michel T, et al. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19[J]. N Engl J Med, 2020, 382(17):1653-1659.
[19]Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19) [J]. JAMA Cardiol, 2020, 5(11):1265-1273.
[20]Bhatla A, Mayer MM, Adusumalli S, et al. COVID-19 and cardiac arrhythmias [J]. Heart Rhythm, 2020, 17 (9):1439-1444.
[21]Inciardi RM, Lupi L, Zaccone G, et al. Cardiac Involvement in a patient with Coronavirus Disease 2019 (COVID-19) [J]. JAMA Cardiol, 2020, 5(7):819-824.
[22]Kim IC, Kim JY, Kim HA, et al. COVID-19-related myocarditis in a 21-year-old female patient[J]. Eur Heart J, 2020, 41(19):1859.
[23]Sala S, Peretto G, Gramegna M, et al. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection[J]. Eur Heart J, 2020, 41(19):1861-1862.
[24]Tavazzi G, Pellegrini C, Maurelli M, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock[J]. Eur J Heart Fail, 2020, 22(5):911-915.
[25]Fox SE, Akmatbekov A, Harbert JL, et al. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans[J]. Lancet Respir Med, 2020, 8(7):681-686.
[26]Chen T, Wu D, Chen HL, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study[J]. BMJ, 2020, 368:m1091.
[27]Creel-Bulos C, Hockstein M, Amin N, et al. Acute cor pulmonale in critically ill patients with Covid-19[J]. N Engl J Med, 2020, 382(21):e70.
[28]Tersalvi G, Vicenzi M, Calabretta D, et al. Elevated troponin in patients with Coronavirus Disease 2019 (COVID-19): possible mechanisms[J]. J Card Fail, 2020, 26(6):470-475.
[29]Bandyopadhyay D, Akhtar T, Hajra A, et al. COVID-19 Pandemic: Cardiovascular Complications and Future Implications[J]. Am J Cardiovasc Drugs, 2020, 20(4):311-324.
[30]Lax SF, Skok K, Zechner P, et al. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series[J]. Ann Intern Med, 2020, 173(5):350-361.
[31]Wichmann D, Sperhake JP, Lutgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: A Prospective Cohort Study[J]. Ann Intern Med, 2020, 173(4):268-277.
[32]Cui SP, Chen S, Li XN, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia[J]. J Thromb Haemost, 2020, 18(6):1421-1424.
[33]Bangalore S, Sharma A, Slotwiner A, et al. ST-segment elevation in patients with Covid-19 — a case series[J]. N Engl J Med, 2020, 382(25):2478-2480.
[34]Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy[J]. J Thromb Haemost, 2020, 18(5):1094-1099.
[35]Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endothelilitis in COVID-19[J]. Lancet, 2020, 395(10234):1417-1418.
[36]Maier CL, Truong AD, Auld SC,et al. COVID19-associated hyperviscosity: a link between inflammation and thrombophilia?[J]Lancet, 2020, 395(10239):1758-1759.
[37]Chen L, Li XJ, Chen MQ, et al. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2[J]. Cardiovasc Res, 2020, 116(6):1097-1100.
[38]Sharma A, Garcia G, Wang YZ, et al. Human iPSC-Derived Cardiomyocytes are Susceptible to SARS-CoV-2 Infection[J]. Cell Rep Med, 2020, 1(4):100052.
[39]Xu Z, Shi L, Wang YJ, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020, 8(4):420-422.
[40]Lindner D, Fitzek A, Brauninger H, et al. Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases[J]. JAMA Cardiol, 2020, 5(11):1281-1285.
[41]Chen NS, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet, 2020, 395(10223):507-513.
[42]Mehta P, McAuley DF,Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression [J]. Lancet, 2020, 395(10229):1033-1034.
[43]Liu YX, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lunginjury[J]. Sci China Life Sci, 2020, 63(3):364-374.
[44]Souilhol C, Serbanovic-Canic J, Fragiadaki M, et al. Endothelial responses to shear stress in atherosclerosis: a novel role for developmental genes[J]. Nat Rev Cardiol, 2020, 17(1):52-63.
[45]Li XR, Sun XD, Carmeliet P.Hallmarks of Endothelial Cell Metabolism in Health and Disease[J]. Cell Metab, 2019, 30(3):414-433.
[46]Chorin E, Dai M, Shulman E, et al. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin[J]. Nat Med, 2020, 26(6):808-809.
[47]赵承奇,靳增华,王雪芬,等.新型冠状病毒肺炎治疗药物的研究进展[J].东南国防医药,2021,23(1):58-63.

相似文献/References:

[1]张严高,余磊,王建莉,等.地塞米松预处理减轻异丙肾上腺素所致心肌损伤及TNF-α的表达[J].医学研究与战创伤救治(原医学研究生学报),2015,17(05):467.[doi:10.3969/j.issn.1672-271X.2015.05.006]
　ZHANG Yan-Gao,YU Lei,WANG Jian-li,et al.Dexamethasone pretreatment reduces isoproterenol-induced myocardial injury and the expression of TNF-α[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(1):467.[doi:10.3969/j.issn.1672-271X.2015.05.006]
[2]李 想,丁江华,李起栋.心率减速力与表阿霉素所致心肌损伤的相关性分析[J].医学研究与战创伤救治(原医学研究生学报),2015,17(06):587.[doi:10.3969/j.issn.1672-271X.2015.06.008]
　LI Xiang,DING Jiang-hua,LI Qi-dong..Relative analysis of between deceleration capacity of heart rate and epirubicin-induced cardiotoxicity[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(1):587.[doi:10.3969/j.issn.1672-271X.2015.06.008]
[3]沈国栋,谭伟龙.新型冠状病毒肺炎流行期间军队医疗机构面临的采供血和输血风险与安全防护[J].医学研究与战创伤救治(原医学研究生学报),2020,22(4):342.[doi:10.3969/j.issn.1672-271X.2020.04.002]
　SHEN Guo-dong,TAN Wei-long.Risk and safety of blood collection and transfusion in military medical institutions during COVID-19 epidemic[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2020,22(1):342.[doi:10.3969/j.issn.1672-271X.2020.04.002]
[4]杨艳,王佳佳,汪文妮,等.新型冠状病毒肺炎期间军队医院老年病房的防控管理[J].医学研究与战创伤救治(原医学研究生学报),2020,22(4):434.[doi:10.3969/j.issn.1672-271X.2020.04.024]
[5]郑翠霞,崔绘丽,吴栋云,等.新型冠状病毒肺炎恢复期血浆治疗对重型患者活动耐力的影响[J].医学研究与战创伤救治(原医学研究生学报),2020,22(5):487.[doi:10.3969/j.issn.1672-271X.2020.05.008]
　ZHENG Cui-xia,7,CUI Hui-li,et al.Novel coronavirus pneumonia recovery plasma treatment on heavy patient’s activity endurance influence[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2020,22(1):487.[doi:10.3969/j.issn.1672-271X.2020.05.008]
[6]王颖,钟勇,金涛,等.新型冠状病毒肺炎期间做好军队老干部防疫工作的实践与思考[J].医学研究与战创伤救治(原医学研究生学报),2020,22(5):552.[doi:10.3969/j.issn.1672-271X.2020.05.026]
[7]陈伟,施涛,王少华,等.新型冠状病毒肺炎疫情期间医院发热诊区的军队人员管理实践[J].医学研究与战创伤救治(原医学研究生学报),2020,22(5):555.[doi:10.3969/j.issn.1672-271X.2020.05.027]
[8]金娥,陈珺,陈丽珍,等.新型冠状病毒肺炎疫情期间血液净化室防控实践[J].医学研究与战创伤救治(原医学研究生学报),2020,22(5):558.[doi:10.3969/j.issn.1672-271X.2020.05.028]
[9]周莉萍,黄迎春,浦嘉丽,等.思维导图在新型冠状病毒肺炎疫情期间辅助护士优化预检筛查流程中的应用[J].医学研究与战创伤救治(原医学研究生学报),2020,22(6):658.[doi:10.3969/j.issn.1672-271X.2020.06.023]
[10]袁力,陈醒,孙伟,等.援鄂医疗队在抗击新型冠状病毒肺炎中的药品保障实践与思考[J].医学研究与战创伤救治(原医学研究生学报),2020,22(6):661.[doi:10.3969/j.issn.1672-271X.2020.06.024]

备注/Memo

备注/Memo:
基金项目：甘肃省自然科学基金（18JR3RA402）;西北民族大学课题（31920200012）
更新日期/Last Update: 2022-02-21